Truist Securities cuts ArriVent BioPharma price target to $18
Truist Securities reduced its ArriVent BioPharma price target to $18.00 per share from $45.00, according to Benzinga ratings actions.
Story updates
03:43:52 PM UTC
SquawkNews
ArriVent BioPharma Is Maintained at Buy by Truist Securities